Stage 4 Lung Cancer Survivor Joins Rare Trial in Houston

When doctors found a suspicious tumor in Lorie Young's lung during a routine physical in March 2026, genetic testing revealed something extraordinary: her stage 4 lung cancer had an NTRK1 fusion, a mutation so rare it appears in just 0.1 to 0.2% of all lung cancer cases.

That rarity became her advantage. At UT MD Anderson in Houston, thoracic oncologist Dr. Eric Singhi offered her a Phase 2 clinical trial for TL-118, a targeted therapy designed specifically for cancers with her exact genetic alteration.

Lorie didn't hesitate. Working in the pharmaceutical industry, she understood that unapproved drugs aren't necessarily unsafe, they're just still being studied before FDA approval.

The genetic testing results meant doctors could match treatment to the specific biology of her cancer, not just treat lung cancer generically. Because her tumor had already spread beyond the lung, surgery wasn't an option, making the targeted therapy trial even more crucial.

Dr. Singhi explained she would be the only lung cancer patient on this trial in the Houston area, given how rare her mutation is. He also reassured her that FDA-approved backup options existed if the targeted therapy didn't work.

The experience transformed Lorie's understanding of cancer research. She had always wondered where all that fundraising money went, but now she sees the massive strides beyond traditional chemotherapy and radiation.

Why This Inspires

Lorie's colleague's saying about Parkinson's disease applies perfectly to cancer too: "If you've met one patient, you've met one patient." Every cancer is different, which makes genetic testing and personalized treatment so powerful.

Her story shows why precision medicine matters. A decade ago, a rare mutation like hers might have meant fewer options. Today, researchers are developing treatments for even the most uncommon genetic abnormalities, turning what once seemed like bad luck into a pathway for hope.

The trial represents something bigger than one patient. Every person who joins a clinical trial helps researchers understand whether new treatments work, potentially opening doors for thousands of future patients with similar mutations.

Lorie's willingness to be the only lung cancer patient on this trial in her area means she's not just fighting for herself, she's contributing data that could help others with NTRK1 fusions get access to life-changing treatments.

Cancer research isn't just raising money anymore, it's delivering real results that transform individual lives through treatments tailored to each person's unique genetic makeup.